Sorafine Cremogel

Manufacturer
Pella Pharmaceuticals Co. Ltd
Effective date
2021-12-02
Label type
HUMAN OTC DRUG LABEL
Version
368
Source
full-release
Hydrated at
2026-05-31 23:45:32

Label at a glance#

ProductSorafine Cremogel
Active ingredientJOJOBA OIL
Label structure14 sections

Dosage and administration

Apply Sorafine ® and spread it well, it will help the skin to offset the loss of natural oils by washing or using certain medications, and also helps to stop and prevent irritation that soap can cause to the skin. Can be used as often as needed.

Storage and handling

Store at a temperature below 30 ° C.

Label contents#

Full prescribing information#

Forms and Presentation

HOW SUPPLIED SECTION

Cream-Gel: Tube of 75 g.

Active Ingredient

OTC - ACTIVE INGREDIENT SECTION

Simmondsia Chinensis (Jojoba) Seed Oil

Inactive Ingredients

INACTIVE INGREDIENT SECTION

Aqua, Glycerin, Cetyl Alcohol, Polysorbate 80, Cera Alba, Xanthan Gum, Carbomer, Methylparaben, Propylparaben, Triethanolamine and BHA.

Purpose

OTC - PURPOSE SECTION

Moisturizer

Properties

DESCRIPTION SECTION

Sorafine ® Cremogel is a hydrating and nourishing Cream-Gel for oily and acne prone skin.
Soothing jojoba extract.

Indications

INDICATIONS & USAGE SECTION

Serafine ® Cremogel is used as a moisturizing and nourishing Gel - Cream for oily and acne prone skin, it is recommended for dry and sensitive skin, eczema, flaky skin, and similar skin problems.
Serafine ® Cremogel prevents skin dryness and reduces roughness, relieves itching, gives a feeling of comfort and softness.
Serafine ® Cremogel is distinguished by its non-fat composition, and contains jojoba oil which is suitable for oily skin, because of the similarity between its composition and the natural oils of the skin; which gives you a wonderful feeling of softness.

Precautions

OTC - KEEP OUT OF REACH OF CHILDREN SECTION

Keep out of reach of children

Warnings

WARNINGS SECTION

  • For external use only
  • Do not apply to broken or irritated skin.

Contraindications

CONTRAINDICATIONS SECTION

Hypersensitivity to any of the components.

Side effects

ADVERSE REACTIONS SECTION

Sorafine ® Cremogel has no known side effects, it is used safely.

Dosage and administration

DOSAGE & ADMINISTRATION SECTION

Apply Sorafine ® and spread it well, it will help the skin to offset the loss of natural oils by washing or using certain medications, and also helps to stop and prevent irritation that soap can cause to the skin.
Can be used as often as needed.

Storage conditions

STORAGE AND HANDLING SECTION

Store at a temperature below 30 ° C.

Primary Package

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Primary PackagePrimary Package

Secondary Package

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Secondary PackageSecondary Package

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
82160-368-01Sorafine Cremogel75 g in 1 TUBECREAM75368
82160-368-01Sorafine Cremogel1 in 1 CARTONCREAM1368

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
82160-368SORAFINE CREMOGEL (SIMMONDSIA CHINENSIS (JOJOBA) SEED OIL) CREAM [PELLA PHARMACEUTICALS CO. LTD]368Legacy NDC, 2 package rows20211209_d228b8e0-0e30-ed39-e053-2a95a90a97e2.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 14 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
82160-36882160-368-01

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
d228b8e0-0e31-ed39-e053-2a95a90a97e2d228b8e0-0e30-ed39-e053-2a95a90a97e22021-12-02Warnings, Adverse reactionsExact identifier
spl id: d228b8e0-0e31-ed39-e053-2a95a90a97e2
spl set id: d228b8e0-0e30-ed39-e053-2a95a90a97e2

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.